Odalprofen was used as an analgesic. Information about the current use of this compound is not available.

Mariptiline is an antidepressant compound.

FENPRINAST is a cromotyn-like bronchodilator used for the treatment of allergy and exercise-induced asthma.

Filibuvir (PF-868554), being developed by Pfizer, is an orally administered, non-nucleoside inhibitor of the HCV NS5B RNA-dependent RNA polymerase for the potential treatment of chronic hepatitis C (HCV) infection. Filibuvir is a potent and specific inhibitor of the virally encoded NS5B polymerase, and inhibited genotype 1 sub genomic HCV replication in the cell-based replicon system. In phase I and a IIa clinical trial in treatment-naïve patients infected with genotype 1 HCV, filibuvir monotherapy or in combination with pegylated IFNα2a/ribavirin (the standard of care [SoC] for HCV infection) for up to 4 weeks significantly reduced HCV RNA levels compared with placebo or SoC alone. However, company stopped development of the drug and the decision to halt development of the non-nucleoside polymerase inhibitor, which was in mid-stage testing, was not related to any safety issues.

GSK-923295 is a small-molecule inhibitor of the mitotic kinesin centromere-associated protein E (CENP-E), and the third novel drug candidate to arise from Cytokinetics' broad strategic alliance with GlaxoSmithKline (GSK). GSK-923295 demonstrated a broad spectrum of activity against a range of human tumor xenografts grown in nude mice, including models of colon, breast, ovarian, lung and other tumors. GSK-923295 is the first drug candidate to enter human clinical trials that specifically targets CENP-E and is currently in Phase I human clinical trials being conducted by GSK. GSK-923295 inhibited release of inorganic phosphate and stabilized CENP-E motor domain interaction with microtubules. Inhibition of CENP-E motor activity in cultured cells and tumor xenografts caused failure of metaphase chromosome alignment and induced mitotic arrest, indicating that tight binding of CENP-E to microtubules is insufficient to satisfy the mitotic checkpoint. Consistent with genetic studies in mice suggesting that decreased CENP-E function can have a tumor-suppressive effect, inhibition of CENP-E induced tumor cell apoptosis and tumor regression.

FENLEUTON is a potent, reversible and selective inhibitor of 5-lipoxygenase with IC50 values ranging from 80 to 1100 nM. It was studied for potential use in veterinary medicine to treat chronic obstructive pulmonary disease in horses.

Intriptyline is a dibenzocycloheptene derivative and mixed monoamine reuptake inhibitor patented by Laboratoires du Docteur Jacques Auclair as tricyclic antidepressant.

Dametralast is an antihistamine agent. Bronchodilator action of dametralast was demonstrated on the isolated trachea of guinea pigs. Dametralast prevents bronchospasm in anesthetized guinea-pigs, protects mice from anaphylactic shock induced by injection of bovine albumin, and has a protective effect in passive cutaneous anaphylaxis test in rats. Investigations into the mechanism of action have shown that the drug was ineffective on the synthesis of cyclooxygenase products from arachidonic acid. Dametralast inhibited cAMP phosphodiesterase (PDE) but this inhibition does not seem to be involved in their anti-inflammatory activity. In clinical tests dametralast was well tolerated; functional respiratory exploration determinations provided the same bronchodilator effect found in animals. A favorable effect was noted in asthmatic subjects and in subjects suffering from respiratory insufficiency.